HOME >> MEDICINE >> NEWS
Medication shows modest benefit in reducing weight, improving HDL, triglyceride levels

Use of the weight-loss medication rimonabant produced modest yet sustained weight loss after 2 years, and improved HDL cholesterol and triglyceride levels, according to a study in the February 15 issue of JAMA.

Approximately two-thirds of U.S. adults are overweight or obese, which greatly increases the risk of developing diabetes mellitus and cardiovascular disease and death from related causes. Researchers believe that besides weight loss, obesity management should target improvement in certain cardiometabolic risk factors, which include abnormal cholesterol and glucose (blood sugar) levels and excess weight around the waist, according to background information in the article. Long-term weight management remains a challenge for patients and clinicians.

F. Xavier Pi-Sunyer, M.D., of St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, and colleagues evaluated the efficacy and safety of the weight-loss medication rimonabant in conjunction with diet and exercise in promoting reductions in body weight and waist circumference, long-term weight maintenance, and reduction of cardiometabolic risk factors in obese and higher risk overweight patients. The randomized, double-blind, placebo-controlled study, conducted from August 2001 to April 2004, included 3,045 adults who were obese (body mass index 30 or greater) or overweight (body mass index greater than 27 and treated or untreated hypertension [high blood pressure] or dyslipidemia [abnormal levels of certain lipids and lipoproteins in the blood]). Patients were randomized to receive placebo, 5 mg/d of rimonabant, or 20 mg/d of rimonabant for 1 year. Rimonabant-treated patients were re-randomized to receive placebo or continued to receive the same rimonabant dose while the placebo group continued to receive placebo during year 2.

Year 1 of the study was completed by 51 percent of patients in the placebo group, 51 percent in the 5 mg of rimonabant
'"/>

Contact: Elizabeth Streich
212-305-6535
JAMA and Archives Journals
14-Feb-2006


Page: 1 2

Related medicine news :

1. Medication does not appear to offer benefit for certain heart attack patients undergoing PCI
2. Medication errors affect childrens leukemia treatment
3. Medication may promote opening of arteries following stroke
4. IOM Advisory: Preventing Medication Errors News Conference on July 20
5. Medication use linked to farmers injuries
6. Medication plus oral contraceptive may improve female pattern hair loss
7. Medication reduces risk of adverse events for patients with acute coronary syndromes undergoing PCI
8. Medications that lower blood pressure linked to reduced risk of Alzheimers disease
9. Medication plus beta-blocker helps prevent shocks from implantable cardioverter defibrillator
10. Medications and cough syrups may cause cavities
11. Medication reduces risk of heart irregularities after cardiac surgery

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... Petersburg Florida (PRWEB) , ... March 28, 2017 , ... ... Marine Corp to raise money to for the Toys for Tots Literacy Campaign at ... federal budget in excess of $70 billion, the U.S. ranks at number 14 internationally ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally ... the “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists ... be aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... NJ (PRWEB) , ... March 28, 2017 , ... ... Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy ... their team of professional staff discussed strategies for preventing outbreaks among camp communities ...
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... Israel . This new business entity, Emosis Ltd, headquartered in ... research and development of novel assays complementing the mother company existing ... locally support commercialization and sales development of Emosis kits. ... This strategic move starts building ...
(Date:3/28/2017)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical ... other unmet medical needs, announced today two poster ... annual meeting.  The first poster to be presented ... ENMD-2076 in Combination with Anti-PD1 in Syngeneic Cancer ... presented on April 4 is entitled " Kinase ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology:
Cached News: